Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Lanham O Dell & Company Inc.

Lanham O Dell & Company Inc. lessened its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 15.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,000 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the quarter. Catalyst Pharmaceuticals comprises about 0.2% of Lanham O Dell & Company Inc.’s holdings, making the stock its 16th largest holding. Lanham O Dell & Company Inc.’s holdings in Catalyst Pharmaceuticals were worth $338,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 819 shares during the period. nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $50,000. CWM LLC increased its position in shares of Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at about $70,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Catalyst Pharmaceuticals in the second quarter valued at about $153,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares in the company, valued at $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock worth $4,018,188 over the last 90 days. 11.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CPRX has been the topic of a number of research analyst reports. HC Wainwright boosted their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Stock Up 2.1 %

NASDAQ:CPRX opened at $21.46 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.89 and a 52 week high of $21.85. The company has a market cap of $2.53 billion, a price-to-earnings ratio of 39.74, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76. The company has a fifty day simple moving average of $20.27 and a two-hundred day simple moving average of $17.50.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. On average, analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.